EWTX as reported
- Net Income
- −$197M
Net Income · +31% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$159M
Free Cash Flow · +26% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.86
EPS · +20% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$197M | +31% | Q2 2026 |
| EPS | −$1.86 | +20% | Q2 2026 |
| ROE | −35% | n/a | Q2 2026 |
| ROA | −33% | n/a | Q2 2026 |
| Free Cash Flow | −$159M | +26% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Edgewise Therapeutics, Inc. (EWTX) - Net IncomeNet IncomeEdgewise Therapeutics, Inc. (EWTX)